Analytical Data
-
基因名
E1A
- Application
-
别名
Early E1A 32 kDa protein
-
种属
Pan-species (General)
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P03255
-
表达区间
Met1~Tyr184
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E1A proteins, derived from adenoviruses, have garnered significant attention in molecular biology and cancer research due to their unique ability to modulate cellular processes. Initially discovered for their role in viral replication, E1A proteins function as transcriptional regulators by interacting with various cellular proteins, including tumor suppressors like pRb (retinoblastoma protein) and p300/CBP (CREB-binding protein). This interaction disrupts normal cell cycle regulation and promotes cell proliferation, making E1A a potent oncogene. Researchers have leveraged E1A's properties to explore its potential in gene therapies and cancer treatments, aiming to harness its ability to induce apoptosis in cancer cells while sparing normal cells. Furthermore, E1A's mechanism of action provides valuable insights into the molecular pathways governing cell growth and differentiation, contributing to a better understanding of tumorigenesis. As a result, ongoing studies focus on the therapeutic applications of E1A, including its use in oncolytic virotherapy, where modified adenoviruses carrying the E1A gene are designed to selectively target and kill malignant cells, thus offering a promising strategy for cancer treatment.
